EMA’s stepwise PIP – Toward regulatory integration after successful pilot

Following the positive review of the stepwise paediatric investigation plan (sPIP) pilot, first published in February 2026, the European Medicines Agency (EMA) is planning to conclude the pilot phase and integrate the sPIP framework into the existing paediatric regulatory landscape on a voluntary basis.
European Biotech Act to strengthen biotechnology and manufacturing sectors

On 16 December 2025 the European Commission published a proposal for a framework of measures to strengthen the Union’s biotechnology and biomanufacturing sectors particularly in the area of health; the so-called Biotech Act.
China’s strategic shift toward global biopharmaceutical innovation

Chinese pharmaceutical and biotech companies are increasingly seeking to expand beyond domestic borders, with particular interest in entering European (EU/EEA) markets – an ambition further accelerated by U.S. tariff policies. Over the past two decades, China has rapidly evolved into a global leader in biopharmaceutical innovation, propelled by significant investments in research, strong advancements in […]
EMA recommendations for human medicines in 2025

In 2025, 104 new medicines were recommended for marketing authorisation with 38 of these having new active substances not previously authorised in the Union.
EU reaches landmark agreement on pharmaceutical legislation reform

On 11 December 2025, the Council of the EU and the European Parliament concluded negotiations on the long-awaited reform of the EU pharmaceutical legislation, marking the most significant overhaul in over two decades.
Understanding the new EMA variation requirements

The recently updated EMA variation requirements reflect a major revision of both the legal framework and its practical guidance. It is essential to understand the distinct roles of the legally binding Variation Regulation and the accompanying EMA Variation Guideline, as well as the key drivers behind their revision and the practical implications for regulatory submissions.
Promotional compliance – major updates in 2025 for the Nordic region

With 2025 coming to a close, we have seen several important updates to Nordic promotional compliance codes over the past year. This overview highlights the key developments affecting promotional activities in the Nordics and outlines their implications for pharmaceutical and healthcare stakeholders.
EMA strengthens Scientific Advice process for medicines addressing public health threats

The European Medicines Agency’s (EMA) Emergency Task Force (ETF) is strengthening its support for the development of promising medicines and vaccines against public health threats by introducing a new procedure for a combined scientific advice (SA) with input from the EMA, as well as clinical trial and ethics experts at national level.
FAST-EU: Accelerating clinical trials to boost Europe’s competitiveness

The EU’s appeal as a region for conducting clinical trials has declined, with the share of clinical trials sharply dropping over the past decade. Although progress has been made to reverse this trend, many challenges still remain for companies conducting trials in the region.
The new FASS improves user experience

Fass (FASS) has, since 1966, been the central source of quality-assured pharmaceutical information in Sweden. 25 years ago, Fass went online for the first time. On November 8, the new Fass was launched, marking the most significant update and modernisation since its inception.